Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems • Medical Devices & Mechanical Engineering
11 pending office actions • 10 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
ETH ZÜRICH has 11 pending office actions in Biotechnology & Pharmaceuticals. The actions involve 11 distinct examiners and 10 distinct art units. Examiner assignments are fully separate, while the art-unit distribution shows limited repetition across the biotechnology matters.
OH, HARRY Y is the busiest examiner, with 1 pending matter. The profile does not show a dominant examiner relationship. Prosecution planning should therefore emphasize the individual application record, with cross-application review reserved for recurring technical or claim issues identified within the art-unit assignments.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (27%) |
| §112 only | 3 (27%) |
| Double-patenting + other | 1 (9%) |
| Multi-statute (no §101) | 4 (36%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OH, HARRY Y | 1 | 85.4% | +16.7% |
| WASEEM, HUMA | 1 | 17.5% | +20.2% |
| LANE, DANIEL E | 1 | 3.8% | +8.3% |
| FERNANDES, PATRICK M | 1 | 59.9% | +31.6% |
| AHMAD, KHALIL ALI | 1 | — | — |
| SKELDING, ZACHARY S | 1 | 59.8% | +41.1% |
| WOOD, BLAKE ANDREW | 1 | 72.1% | +13.6% |
| PIRO, NICHOLAS ANTHONY | 1 | 47.5% | +41.3% |
| HERNANDEZ, JACKSON J | 1 | 50.7% | +39.2% |
| ALLEN, MICHAEL D | 1 | 31.9% | +48.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19366684 | CONTROLLED FLIGHT OF A MULTICOPTER EXPERIENCING A FAILURE AFFECTING AN EFFECTOR | OH, HARRY Y | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18000242 | RNA MOLECULES FOR THE TREATMENT OF CANCER | ALLEN, MICHAEL D | 183d overdue |
| 18394287 | ROBOTICS DEVICE CONTROL SIGNALS BASED ON MOVEMENT DATA | WOOD, BLAKE ANDREW | 9d |
| 18001074 | SMALL-MOLECULE INHIBITORS OF THE FRS2-FGFR INTERACTION AND THEIR USE IN MEDICINE, IN THE PREVENTION AND TREATMENT OF CANCER | HERNANDEZ, JACKSON J | 29d |
| 19103245 | METHOD FOR DETERMINING A FATIGUE VALUE OF A PERSON | LANE, DANIEL E | 42d |
| 19166421 | SYSTEM AND METHOD FOR PROVIDING PREDICTION FOR PHYSIOLOGICAL PARAMETER OF PATIENT | WASEEM, HUMA | — |
| 18874716 | MAGNETICALLY STEERABLE DEVICE FOR USE INSIDE OF A MAMMALIAN BODY | FERNANDES, PATRICK M | — |
| 18572051 | Method for producing calcium carbonate solids from alkaline minerals | PIRO, NICHOLAS ANTHONY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18000242 | RNA MOLECULES FOR THE TREATMENT OF CANCER | ALLEN, MICHAEL D | 183d overdue |
| 18394287 | ROBOTICS DEVICE CONTROL SIGNALS BASED ON MOVEMENT DATA | WOOD, BLAKE ANDREW | 9d |
| 18001074 | SMALL-MOLECULE INHIBITORS OF THE FRS2-FGFR INTERACTION AND THEIR USE IN MEDICINE, IN THE PREVENTION AND TREATMENT OF CANCER | HERNANDEZ, JACKSON J | 29d |
| 19366684 | CONTROLLED FLIGHT OF A MULTICOPTER EXPERIENCING A FAILURE AFFECTING AN EFFECTOR | OH, HARRY Y | — |
| 19166421 | SYSTEM AND METHOD FOR PROVIDING PREDICTION FOR PHYSIOLOGICAL PARAMETER OF PATIENT | WASEEM, HUMA | — |
| 18874716 | MAGNETICALLY STEERABLE DEVICE FOR USE INSIDE OF A MAMMALIAN BODY | FERNANDES, PATRICK M | — |
| 18437678 | CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE | SKELDING, ZACHARY S | — |
| 18572051 | Method for producing calcium carbonate solids from alkaline minerals | PIRO, NICHOLAS ANTHONY | — |
| Art Unit | Apps |
|---|---|
| 3657 | 1 |
| 3686 | 1 |
| 3715 | 1 |
| 3791 | 1 |
| 1644 | 1 |
| 3658 | 1 |
| 1738 | 1 |
| 1627 | 1 |
| 1671 | 1 |
| 1616 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19366684 | CONTROLLED FLIGHT OF A MULTICOPTER EXPERIENCING A FAILURE AFFECTING AN EFFECTOR | OH, HARRY Y | 3657 | §112Other | Non-Final OA | — | Pending | Oct 23, 2025 |
| 19166421 | SYSTEM AND METHOD FOR PROVIDING PREDICTION FOR PHYSIOLOGICAL PARAMETER OF PATIENT | WASEEM, HUMA | 3686 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 17, 2025 |
| 19103245 | METHOD FOR DETERMINING A FATIGUE VALUE OF A PERSON | LANE, DANIEL E | 3715 | §101§102§112 | Non-Final OA | 42d | Pending | Feb 12, 2025 |
| 18874716 | MAGNETICALLY STEERABLE DEVICE FOR USE INSIDE OF A MAMMALIAN BODY | FERNANDES, PATRICK M | 3791 | §102§103§112 | Non-Final OA | — | Pending | Dec 13, 2024 |
| 18865782 | DISTANCE MEASURING | AHMAD, KHALIL ALI | — | §112 | Non-Final OA | — | Pending | Nov 14, 2024 |
| 18437678 | CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE | SKELDING, ZACHARY S | 1644 | §112Other | Non-Final OA | — | Pending | Feb 09, 2024 |
| 18394287 | ROBOTICS DEVICE CONTROL SIGNALS BASED ON MOVEMENT DATA | WOOD, BLAKE ANDREW | 3658 | §102§103 | Final Rejection | 9d | Pending | Dec 22, 2023 |
| 18572051 | Method for producing calcium carbonate solids from alkaline minerals | PIRO, NICHOLAS ANTHONY | 1738 | §102§103§112 | Non-Final OA | — | Pending | Dec 19, 2023 |
| 18001074 | SMALL-MOLECULE INHIBITORS OF THE FRS2-FGFR INTERACTION AND THEIR USE IN MEDICINE, IN THE PREVENTION AND TREATMENT OF CANCER | HERNANDEZ, JACKSON J | 1627 | §103§112 | Final Rejection | 29d | Pending | Jun 22, 2023 |
| 18000242 | RNA MOLECULES FOR THE TREATMENT OF CANCER | ALLEN, MICHAEL D | 1671 | §101§112 | Non-Final OA | 183d overdue | Pending | Nov 29, 2022 |
| 17620208 | CROSSLINKABLE HYDROGEL COMPOSITIONS | ARMSTRONG, SUSANNAH SIPPLE | 1616 | §103DP | Final Rejection | — | Pending | Dec 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialETH ZÜRICH has 11 pending office actions as of October 2026, spread across 10 art units and 11 examiners.
Harry Y Oh has the most, with 1 of ETH ZÜRICH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
